Drugs / Allogeneic Adipose-derived Mesenchymal Stem Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05789394 | Jun 2023 → Jul 2027 expected | IDH-wildtype glioblastoma, astrocytoma, IDH-mutant, grade 4 | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT04388761 | Sep 2020 → Feb 2024 | ischemic disease | Tambi Jarmi | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07048314 | Jul 2026 → Jun 2027 expected | erectile dysfunction, prostate cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic adipose-derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07048314 ↗ |
| Known as | AMSCs | “adipose-derived mesenchymal stem cells (AMSCs)” NCT05789394 ↗ |
| Modality | Cell therapy | “Allogeneic Adipose-derived Mesenchymal Stem Cells” NCT05789394 ↗ |
| Route | Other | “5 subjects will receive AMSCs via direct injection into the kidney parenchyma only” NCT04388761 ↗ |